The
global Antibiotic
Resistance Market size is expected to reach USD 12.48 billion by
2030, registering a CAGR of 5.27% from 2024 to 2030, according to a new report
by Grand View Research, Inc. Rise in the number of antibiotic-resistant
infections due to misuse or overuse of antibiotics is a major factor
attributing to market growth. Moreover, the increasing patient base across the
globe and high costs associated with the treatment of diseases is anticipated
to boost the market growth over the forecast period.
The
prevalence of gram-negative infections is increasing at an alarming rate. These
infections have lesser treatment options available in the market. The high
unmet needs result in high demand for new therapies and, therefore, small and
medium-sized pharmaceutical companies are actively involved in the development
of novel treatment options. Moreover, the government and other organizations
are also aiding research activities to drive the development of innovative
therapies.
Multiple
mid-level biotechnology companies have entered the arena with targeted
therapies for antibiotic-resistant infections. Various manufacturers are
developing therapies, especially for drug-resistant infections, that target a
smaller population subset.
The
U.S. government in alliance with BARDA is supporting several companies to boost
the development of new therapies for antibiotic-resistant diseases. BARDA has
also been associated with pharmaceutical companies such as GSK; Tetraphase;
Basilea; Astra Zeneca; and many more. Many countries and international organizations
have formed dedicated groups or alliances to monitor and study the pattern of
drug-resistant infections.
For
instance, the WHO has introduced the Global Antimicrobial Resistance
Surveillance System (GLASS) to monitor antibiotic-resistant infections at a
global level. Similarly, the Public Health Agency of Canada has introduced the
Canadian Antimicrobial Resistance Surveillance System (CARSS) to study
drug-resistant infections pattern at the country level.
However,
according to a review published by WHO in March 2023, the antibiotics pipeline
activities are limited, with only 12 new antibiotics being approved between
2017 and 2021. The review further stated that there are only 27 new candidates
under development, out of which only 6 are considered “innovative” enough to be
capable of overcoming antibiotic resistance as defined by WHO.
Related Press
Release@ Antibiotic
Resistance Market Report
Antibiotic Resistance Market Report Highlights
- In 2023,
cUTI accounted for the largest market share and is anticipated to maintain
its dominance in the global market in the coming years
- Combination
drugs are expected to grow at the fastest CAGR over the forecast period
- North
America dominated the antibiotic resistance industry in 2023. The target
goals set by the U.S. national action plan in response to the significant
burden of resistant gram-positive and negative infections is the key
factor driving the market
- Asia Pacific
is set to witness the fastest growth over the forecast period due to
excessive consumption of antibiotics, advancements in technology, and
growing awareness about antibiotic resistance testing, treatment, &
management of the same.
Antibiotic Resistance Market
Report Scope
|
Report Attribute |
Details |
|
Market
size value in 2024 |
USD 9.17
billion |
|
Revenue
forecast in 2030 |
USD 12.48
billion |
|
Growth
rate |
CAGR of
5.27% from 2024 to 2030 |
|
Base year
for estimation |
2023 |
|
Historical data |
2018 - 2022 |
|
Forecast period |
2024 - 2030 |
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/5467/rfc
Antibiotic Resistance Market Segmentation
Grand
View Research has segmented the global antibiotic resistance market based on
disease, pathogen, drug class, mechanism of action, distribution channel, and
region:
Antibiotic Resistance Disease Outlook (Revenue, USD
Million, 2018 - 2030)
- cUTI
(Complicated Urinary Tract Infections)
- CDI
(Clostridioides difficile Infection)
- ABSSSI
(Acute bacterial skin and skin structure infections)
- HABP
(Hospital-acquired bacterial pneumonia)
- CABP
(Community-acquired pneumonia)
- cIAI
(Complicated intra-abdominal infection)
- BSI
(Bloodstream infection)
Antibiotic Resistance Pathogen Outlook (Revenue, USD
Million, 2018 - 2030)
- E. coli
- K.
pneumoniae
- P.
aeruginosa
- S. aureus
- A. baumannii
- S.
pneumoniae
- H. influenzae
- C. difficile
- E. faecium
Antibiotic Resistance Drug Class Outlook (Revenue, USD
Million, 2018 - 2030)
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Combination
therapies
- Cephalosporins
- Others
Antibiotic Resistance Mechanism of Action Outlook
(Revenue, USD Million, 2018 - 2030)
- Protein
Synthesis Inhibitors
- Cell Wall
Synthesis Inhibitors
- RNA
Synthesis Inhibitors
- DNA
Synthesis Inhibitors
- Others
Antibiotic Resistance Distribution Channel Outlook
(Revenue, USD Million, 2018 - 2030)
- Hospital
Pharmacies
- Retail
Pharmacies
- Online
Pharmacies
Antibiotic Resistance Regional Outlook (Revenue, USD
Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- Thailand
- South Korea
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
